# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The gross proceeds from the offering are expected to be approximately $3.5 million, prior to deducting placement agent's fe...
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target fro...
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(4.18) per share which missed the analyst consensus estimate o...